Interleukin-2-based biochemotherapy for patients with stage IV melanoma: Long-term survivors outside a clinical trial setting

Oncology

Volumn 73, Issue 1-2, 2008, Pages 33-40

  Hess, Viviane ^a   Herrmann, Richard ^a   Veelken, Hendrik ^b   Schwabe, Michael ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Biochemotherapy; Interleukin 2; Melanoma; Survival, long term disease free; Survival, overall

Indexed keywords

ALPHA2A INTERFERON; CISPLATIN; DACARBAZINE; DOCETAXEL; FOTEMUSTINE; INTERLEUKIN 2; PEGINTERFERON; TAMOXIFEN; TROFOSFAMIDE; VINBLASTINE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON ALFA-2A; INTERLEUKIN-2; KAPLAN-MEIERS ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 41549098377     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000120029     Document Type: Article

References (23)

1. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
2. Legha SS, Ring S, Bedikian A, et al: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferonalpha. Ann Oncol 1996;7:827-835.
3. Keilholz U, Gore ME: Biochemotherapy for advanced melanoma. Semin Oncol 2002;29:456-461.
4. Serrone L, Zeuli M, Sega FM, Cognetti F: Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19:21-34.
5. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood J: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-Coordinated Intergroup Trial (abstract 2847). Proc Am Soc Clin Oncol 2003;22:708.
6. Bajetta E, Del Vecchio M, Nova P, et al: Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006;17:571-577.
7. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-2052.
8. Keilholz U, Goey SH, Punt CJ, et al: Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-2588.
9. Keilholz U, Punt CJ, Gore M, et al: Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005;23:6747-6755.
10. Ridolfi R, Chiarion-Sileni V, Guida M, et al: Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002;20:1600-1607.
11. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-975.
12. Keilholz U, Martus P, Punt CJ, et al: Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 2002;38:1501-1511.
13. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-1759.
14. WHO: Handbook of Reporting Results of Cancer Treatment. Publication No 48. Geneva, World Health Organization, 1979.
15. Pockaj BA, Topalian SL, Steinberg SM, White DE, Rosenberg SA: Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J Clin Oncol 1993;11:136-147.
16. Lindsey KR, Rosenberg SA, Sherry RM: Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol 2000;18:1954-1959.
17. Minor DR, Madland MT, Kashani-Sabet M, Denny SR, Harvey WB: A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity. Cancer Biother Radiopharm 2005;20:479-486.
18. O'Day SJ, Boasberg PD, Piro L, et al: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002;8:2775-2781.
19. Gogas H, Ioannovich J, Dafni U, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-718.
20. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17: 2105-2116.
21. Manola J, Atkins M, Ibrahim J, Kirkwood J: Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782-3793.
22. Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC: Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res 2000;6:3895-3903.
23. Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R: Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 2005;15:199-204.